DK3473619T3 - Aurora a-kinase-hæmmer - Google Patents

Aurora a-kinase-hæmmer Download PDF

Info

Publication number
DK3473619T3
DK3473619T3 DK18204389.3T DK18204389T DK3473619T3 DK 3473619 T3 DK3473619 T3 DK 3473619T3 DK 18204389 T DK18204389 T DK 18204389T DK 3473619 T3 DK3473619 T3 DK 3473619T3
Authority
DK
Denmark
Prior art keywords
aurora
inhibitor
chinese
chinese inhibitor
Prior art date
Application number
DK18204389.3T
Other languages
English (en)
Inventor
James Robert Henry
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3473619T3 publication Critical patent/DK3473619T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18204389.3T 2014-11-14 2015-11-06 Aurora a-kinase-hæmmer DK3473619T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462079742P 2014-11-14 2014-11-14
EP15798602.7A EP3218366B1 (en) 2014-11-14 2015-11-06 Aurora a kinase inhibitor

Publications (1)

Publication Number Publication Date
DK3473619T3 true DK3473619T3 (da) 2020-09-21

Family

ID=54697647

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15798602.7T DK3218366T3 (da) 2014-11-14 2015-11-06 Aurora a-kinase-hæmmer
DK18204389.3T DK3473619T3 (da) 2014-11-14 2015-11-06 Aurora a-kinase-hæmmer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15798602.7T DK3218366T3 (da) 2014-11-14 2015-11-06 Aurora a-kinase-hæmmer

Country Status (41)

Country Link
US (2) US9637474B2 (da)
EP (2) EP3473619B8 (da)
JP (1) JP6159029B2 (da)
KR (1) KR101930182B1 (da)
CN (1) CN107108567B (da)
AR (1) AR102463A1 (da)
AU (1) AU2015347043B2 (da)
BR (1) BR112017007239B1 (da)
CA (1) CA2963473C (da)
CL (1) CL2017001209A1 (da)
CO (1) CO2017004784A2 (da)
CR (1) CR20170158A (da)
CY (2) CY1121334T1 (da)
DK (2) DK3218366T3 (da)
DO (1) DOP2017000111A (da)
EA (1) EA032102B1 (da)
EC (1) ECSP17029203A (da)
ES (2) ES2826448T3 (da)
HR (2) HRP20190324T1 (da)
HU (2) HUE043759T2 (da)
IL (1) IL251406B (da)
JO (1) JO3488B1 (da)
LT (2) LT3473619T (da)
ME (1) ME03325B (da)
MX (1) MX377560B (da)
MY (1) MY188313A (da)
NZ (1) NZ730771A (da)
PE (1) PE20170898A1 (da)
PH (1) PH12017500881B1 (da)
PL (1) PL3218366T3 (da)
PT (2) PT3218366T (da)
RS (2) RS60999B1 (da)
SG (1) SG11201703394RA (da)
SI (2) SI3473619T1 (da)
SV (1) SV2017005418A (da)
TN (1) TN2017000116A1 (da)
TR (1) TR201902686T4 (da)
TW (1) TWI693218B (da)
UA (1) UA117983C2 (da)
WO (1) WO2016077161A1 (da)
ZA (1) ZA201702199B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019230679A1 (ja) * 2018-05-29 2019-12-05 大鵬薬品工業株式会社 抗腫瘍剤及び腫瘍治療方法
AU2019388843B2 (en) * 2018-11-30 2023-03-23 Eli Lilly And Company An Aurora A kinase inhibitor for use in the treatment of neuroblastoma
CN112239465A (zh) * 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
US20240287094A1 (en) 2021-05-24 2024-08-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
TW202321215A (zh) * 2021-07-28 2023-06-01 大陸商北京加科思新藥研發有限公司 Aurora a 選擇性抑制劑的多晶型及其用途
EP4504209A1 (en) 2022-04-08 2025-02-12 Eli Lilly and Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
AU2023383898A1 (en) 2022-11-23 2025-06-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt of nitrogen-containing heterocyclic compound, crystal form thereof, and preparation method therefor
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
CN121039117A (zh) * 2023-05-05 2025-11-28 苏州信诺维医药科技股份有限公司 杂环类化合物、其药物组合物和其应用
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1956982A (zh) * 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
AU2005297848B2 (en) * 2004-10-29 2011-03-17 Msd K.K. Novel aminopyridine derivatives having selective Aurora-A inhibitory effect
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
JP5411152B2 (ja) * 2008-02-22 2014-02-12 Msd株式会社 オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
EP2411011A4 (en) * 2009-03-24 2012-08-15 Msd Kk NEW AMINO-PYRIDINE DERIVATIVES WITH SELECTIVE AURORA A INHIBITION
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof

Also Published As

Publication number Publication date
ES2716732T3 (es) 2019-06-14
US9637474B2 (en) 2017-05-02
ZA201702199B (en) 2018-12-19
CN107108567B (zh) 2020-01-10
US10010540B2 (en) 2018-07-03
EP3218366A1 (en) 2017-09-20
ES2826448T3 (es) 2021-05-18
PE20170898A1 (es) 2017-07-12
EA032102B1 (ru) 2019-04-30
SG11201703394RA (en) 2017-05-30
TN2017000116A1 (en) 2018-07-04
MX2017006275A (es) 2017-08-14
AR102463A1 (es) 2017-03-01
MY188313A (en) 2021-11-27
HRP20201681T1 (hr) 2020-12-25
EP3218366B1 (en) 2019-01-09
HUE043759T2 (hu) 2019-09-30
IL251406A0 (en) 2017-05-29
LT3218366T (lt) 2019-04-10
JO3488B1 (ar) 2020-07-05
CO2017004784A2 (es) 2017-08-31
BR112017007239A2 (pt) 2017-12-19
PT3218366T (pt) 2019-04-01
CN107108567A (zh) 2017-08-29
CY1123592T1 (el) 2022-03-24
US20160137628A1 (en) 2016-05-19
PH12017500881A1 (en) 2017-11-06
MX377560B (es) 2025-03-10
TR201902686T4 (tr) 2019-03-21
ME03325B (me) 2019-10-20
PL3218366T3 (pl) 2019-06-28
RS60999B1 (sr) 2020-11-30
CL2017001209A1 (es) 2018-01-12
CA2963473A1 (en) 2016-05-19
CR20170158A (es) 2017-06-21
AU2015347043A1 (en) 2017-05-04
KR20170066623A (ko) 2017-06-14
PT3473619T (pt) 2020-11-11
EA201790838A1 (ru) 2017-12-29
DK3218366T3 (da) 2019-04-01
IL251406B (en) 2019-08-29
NZ730771A (en) 2018-07-27
UA117983C2 (uk) 2018-10-25
CY1121334T1 (el) 2020-05-29
HRP20190324T1 (hr) 2019-04-19
KR101930182B1 (ko) 2018-12-17
ECSP17029203A (es) 2018-01-31
PH12017500881B1 (en) 2017-11-06
TW201629038A (zh) 2016-08-16
CA2963473C (en) 2018-12-18
JP2016539942A (ja) 2016-12-22
EP3473619A1 (en) 2019-04-24
SI3473619T1 (sl) 2020-10-30
AU2015347043B2 (en) 2018-03-22
RS58347B1 (sr) 2019-03-29
EP3473619B1 (en) 2020-09-09
US20170119751A1 (en) 2017-05-04
DOP2017000111A (es) 2017-06-15
SV2017005418A (es) 2018-10-09
HUE051530T2 (hu) 2021-03-01
EP3473619B8 (en) 2020-11-04
TWI693218B (zh) 2020-05-11
SI3218366T1 (sl) 2019-02-28
JP6159029B2 (ja) 2017-07-05
BR112017007239B1 (pt) 2023-01-31
WO2016077161A1 (en) 2016-05-19
LT3473619T (lt) 2020-11-10

Similar Documents

Publication Publication Date Title
FIC20230037I1 (fi) Glofitamabi
ME03325B (me) Inhibitor aurora a kinaze
DK3094728T3 (da) Kiralt design
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
DK3222714T3 (da) Phytasemutanter
FIC20240047I1 (fi) Frukintinibi
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DE112015001664A5 (de) Betätigungsaktuator
BR112017006123A2 (pt) emulsões o/a
ES1123386Y (es) Un quitasol
DK3213077T3 (da) Malariadetektering
DE112015005041A5 (de) Gargerätevorrichtung
IL249329A0 (en) Resistive composition
DE102014000623A8 (de) Halbhohlnietelement
BR112017005751A2 (pt) emulsões o/a
DK3188963T3 (da) Forbedring af en skrue
FI20145913A (fi) Staattorimekanismi
DE202014005655U8 (de) llluminationsvorrichtung
DE112015001633A5 (de) Betätigungsaktuator
FR3021937B1 (fr) Servofrein a depression
DE112015005055A5 (de) Gargerätevorrichtung
TH1601003589A (th) ควินาโซลิน-thf-เอมีนที่เป็นตัวยับยั้ง pde1
FI10586U1 (fi) Rakennusosa
ES1135467Y (es) Expositor
UA31157S (uk) Саморіз